Stryker Corporation (SYK)
Healthcare · Medical - Devices · Data as of 2026-10-22
Bottom line
SYK is trading near its usual valuation, in the middle of its recent price range, and recent volume suggests money flowing in. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading near its usual range (Yellow)
SYK trades at 31× earnings, below its own 5-year average of 44× and roughly in line with similar healthcare companies we track (28×, 53 peers). That is roughly what the market has typically paid for this stock. Its free-cash-flow yield is about 4.1%. Its current multiple sits around the 2nd percentile of its own last five years — toward the low end of its own range.
Price zones — In the middle of its recent range (Yellow)
At $307.08, the stock sits between its recent support and resistance levels. Over the past year SYK has traded between $267.00 and $392.55; its historical support zone sits near $296.48 and resistance near $325.60. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $267.00–$392.55 · 50-day average $296.48 · 200-day average $325.60
Money flow — Money is flowing in (Green)
Recent trading in SYK shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 1.3× volume on down days over the last 30 sessions.
Dividends & company facts
SYK paid $3.52 a share in dividends over the past year — 1.1% of today's price — and has raised it in each of the last five years. It also bought back shares: $149 million in fiscal 2025, about 0.13% of its market value.
- Dividend yield (12 months)
- 1.15%
- Paid over 12 months
- $3.52 a share
- Payout ratio
- 35.3%
- Buybacks
- 0.13% (fiscal 2025)
- Shares, past year
- -0.1%
- Revenue, 12 months
- $25.8B
- Profit, 12 months
- $3.7B
- Employees
- 56,000
- CEO
- Kevin A. Lobo
- Headquarters
- Portage, MI
- Listed since
- 1980 · NYSE
About the company
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions.
Related stocks
一句话结论
SYK 估值接近其惯常水平，处于近期价格区间的中部，近期成交量显示资金正在流入。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 处于其惯常的估值区间
SYK 目前的市盈率为 31×，低于其自身 5 年平均的 44×，并且大致持平于我们追踪的同类Healthcare公司（28×，53 家）。这大致就是市场以往为这只股票所付出的水平。其自由现金流收益率约为 4.1%。它当前的估值倍数大约位于自身过去五年分布的第 2 百分位——处于自身区间的偏低位置。
价格区间 — 处于近期区间的中部
目前价格为 $307.08，位于其近期的支撑位与阻力位之间。过去一年 SYK 的价格在 $267.00 到 $392.55 之间波动；其历史支撑区在 $296.48 附近，阻力区在 $325.60 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 资金正在流入
SYK 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 1.3×。
股息与公司概况
SYK 过去一年每股派息 3.52 美元，相当于当前股价的 1.1%，过去五年每年都有上调。它也回购了股票：2025 财年回购 1.5亿美元，约占市值的 0.13%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.